173 related articles for article (PubMed ID: 37443605)
1. SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis.
Flockerzi FA; Hohneck J; Saar M; Bohle RM; Stahl PR
Diagnostics (Basel); 2023 Jun; 13(13):. PubMed ID: 37443605
[TBL] [Abstract][Full Text] [Related]
2. THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer.
Flockerzi FA; Hohneck J; Saar M; Bohle RM; Stahl PR
Diagnostics (Basel); 2023 Jan; 13(2):. PubMed ID: 36673031
[TBL] [Abstract][Full Text] [Related]
3. Highly Expressing
Jumai K; Zhang T; Qiao B; Ainiwaer J; Zhang H; Hou Z; Awut I; Niyaz M; Zhang L; Sheyhidin I
J Immunol Res; 2022; 2022():2555647. PubMed ID: 35755171
[TBL] [Abstract][Full Text] [Related]
4. THSD7A Positivity Predicts Poor Survival and Is Linked to High FAK Expression and FGFR1-Wildtype in Female Patients with Squamous Cell Carcinoma of the Lung.
Flockerzi FA; Hohneck J; Langer F; Bohle RM; Stahl PR
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445817
[TBL] [Abstract][Full Text] [Related]
5. Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling.
Huang J; Zheng DL; Qin FS; Cheng N; Chen H; Wan BB; Wang YP; Xiao HS; Han ZG
J Clin Invest; 2010 Jan; 120(1):223-41. PubMed ID: 20038795
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of
Ni Q; Li X; Huang H; Ge Z
Front Oncol; 2023; 13():1015358. PubMed ID: 37035142
[TBL] [Abstract][Full Text] [Related]
7. Scavenger receptor class A, member 5 is associated with thyroid cancer cell lines progression via epithelial-mesenchymal transition.
Zheng C; Xia EJ; Quan RD; Bhandari A; Wang OC; Hao RT
Cell Biochem Funct; 2020 Mar; 38(2):158-166. PubMed ID: 31989658
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SCARA5 inhibits tumor proliferation and invasion in osteosarcoma via suppression of the FAK signaling pathway.
Wen X; Wang N; Zhang F; Dong C
Mol Med Rep; 2016 Mar; 13(3):2885-91. PubMed ID: 26847210
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of SCARA5 may contribute to breast cancer via promoter hypermethylation.
Ulker D; Ersoy YE; Gucin Z; Muslumanoglu M; Buyru N
Gene; 2018 Oct; 673():102-106. PubMed ID: 29908284
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic upregulation of Class A scavenger receptor member 5 inhibits tumor growth and metastasis.
Yan N; Zhang S; Yang Y; Cheng L; Li C; Dai L; Dai L; Zhang X; Fan P; Tian H; Wang R; Chen X; Su X; Li Y; Zhang J; Du T; Wei Y; Deng H
Cancer Sci; 2012 Sep; 103(9):1631-9. PubMed ID: 22642751
[TBL] [Abstract][Full Text] [Related]
11. SCARA5 is a Novel Biomarker in Colorectal Cancer by Comprehensive Analysis.
Liu J; Zeng ML; Shi PC; Cao YP; Zhang JL; Xie YP
Clin Lab; 2020 Jul; 66(7):. PubMed ID: 32658413
[TBL] [Abstract][Full Text] [Related]
12. Carcinoma-associated fibroblasts release microRNA-331-3p containing extracellular vesicles to exacerbate the development of pancreatic cancer
Han Y; Qian X; Xu T; Shi Y
Cancer Biol Ther; 2022 Dec; 23(1):378-392. PubMed ID: 35510828
[TBL] [Abstract][Full Text] [Related]
13. SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression.
Zhang H; Liu C; Wang X; Wang Y; Zheng J
J Cancer; 2021; 12(8):2412-2421. PubMed ID: 33758617
[TBL] [Abstract][Full Text] [Related]
14. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation.
Liu H; Hu J; Wei R; Zhou L; Pan H; Zhu H; Huang M; Luo J; Xu W
J Exp Clin Cancer Res; 2018 Sep; 37(1):229. PubMed ID: 30249289
[TBL] [Abstract][Full Text] [Related]
15. Identification of SCARA5 as a Potential Biomarker for Oral Squamous Cell Carcinoma using MALDI-TOF-MS Analysis.
Liu Y; Tan YR; Sun WW; Ju WT; Fu Y; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
Proteomics Clin Appl; 2018 Sep; 12(5):e1700180. PubMed ID: 29461673
[TBL] [Abstract][Full Text] [Related]
16. CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.
Liu H; Hu J; Pan H; Luo D; Huang M; Xu W
Dig Dis Sci; 2018 Jan; 63(1):155-165. PubMed ID: 29189991
[TBL] [Abstract][Full Text] [Related]
17. SCARA5 plays a critical role in the progression and metastasis of breast cancer by inactivating the ERK1/2, STAT3, and AKT signaling pathways.
You K; Su F; Liu L; Lv X; Zhang J; Zhang Y; Liu B
Mol Cell Biochem; 2017 Nov; 435(1-2):47-58. PubMed ID: 28497372
[TBL] [Abstract][Full Text] [Related]
18. SCARA5 induced ferroptosis to effect ESCC proliferation and metastasis by combining with Ferritin light chain.
Liu Y; Xiong R; Xiao T; Xiong L; Wu J; Li J; Feng G; Song G; Liu K
BMC Cancer; 2022 Dec; 22(1):1304. PubMed ID: 36513999
[TBL] [Abstract][Full Text] [Related]
19. SCARA5 plays a critical role in the commitment of mesenchymal stem cells to adipogenesis.
Lee H; Lee YJ; Choi H; Seok JW; Yoon BK; Kim D; Han JY; Lee Y; Kim HJ; Kim JW
Sci Rep; 2017 Nov; 7(1):14833. PubMed ID: 29093466
[TBL] [Abstract][Full Text] [Related]
20. SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways.
Huang J; Lv C; Zhao B; Ji Z; Gao Z
Open Med (Wars); 2023; 18(1):20230627. PubMed ID: 36785765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
